title: Cardiac sympathetic activation in patients with pulmonary arterial hypertension.
abstract: Patients with congestive heart failure (CHF) due to left ventricular (LV) dysfunction have sympathetic activation specifically directed to the myocardium. Although pulmonary arterial hypertension (PAH) is associated with increased systemic sympathetic activity, its impact on sympathetic drive to ventricular myocardium is unknown. Fifteen patients with PAH (9 women; 54 ± 12 years) were studied: 10 with idiopathic PAH and 5 with a connective tissue disorder. We measured hemodynamics, as well as radiolabeled and endogenous concentrations of arterial and coronary sinus norepinephrine (NE). These measures were repeated after inhaled nitric oxide (NO). Measurement of transcardiac NE concentrations and the cardiac extraction of radiolabeled NE allowed calculation of the corrected transcardiac gradient of NE (CTCG of NE). Comparative data were collected from 15 patients (9 women: 55 ± 12 yr) with normal LV function and 15 patients with CHF (10 women; 53 ± 12 yr). PAH patients had elevated arterial NE concentrations compared with those with normal LV function but were similar to those with CHF. The CTCG of NE was higher in those with PAH than in the normal LV group (3.6 ± 2.2 vs. 1.5 ± 0.9 pmol/ml; P < 0.01) but similar to that seen in those with CHF (3.3 ± 1.4; P = NS). Inhaled NO, which reduced pulmonary artery pressure and increased cardiac output, had no effect on cardiac sympathetic activity. Therefore, cardiac sympathetic activation occurs in PAH. The mechanism of this activation remains uncertain but does not involve elevations in left heart filling pressure.
authors.affiliation: Division of Cardiology, Department of Medicine, Mount Sinai Hospital, University Health Network, Toronto, Canada.
authors.forename: Susanna
authors.initials: S
authors.lastname: Mak
authors.forename: Klaus K
authors.initials: KK
authors.lastname: Witte
authors.forename: Abdul
authors.initials: A
authors.lastname: Al-Hesayen
authors.forename: John J
authors.initials: JJ
authors.lastname: Granton
authors.forename: John D
authors.initials: JD
authors.lastname: Parker
mesh_terms: D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D002302:Cardiac Output / Q000187:drug effects / Q000502:physiology; D065627:Familial Primary Pulmonary Hypertension; D005260:Female; D006321:Heart / Q000294:innervation*; D006333:Heart Failure / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D006439:Hemodynamics / Q000502:physiology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000494:pharmacology; D009638:Norepinephrine / Q000097:blood; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000150:complications / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000502:physiology*
chemical_list: D009569:Nitric Oxide; D009638:Norepinephrine